7.02
-0.08(-1.13%)
Currency In USD
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
8
First IPO Date
December 16, 2021
| Name | Title | Pay | Year Born |
| Dr. Spyridon Papapetropoulos M.D., Ph.D. | Chief Executive Officer, President & Director | 768,263 | 1973 |
| Mr. Adrian Hinton BEC, F.C.A. | Financial Controller | 191,893 | 1952 |
| Ms. Elizabeth Doolin | Senior Vice President of Clinical Development | 198,441 | 1965 |
| Mr. Rajeev Chandra B.Com., C.A., M.B.A. | Company Secretary | 0 | N/A |
| Dr. Mark A. Smith M.D., Ph.D. | Chief Medical Officer | 0 | 1955 |
| Dr. Julie Kerner Ph.D. | Senior Vice President of Business Operations | 0 | N/A |
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.